Welcome to our dedicated page for Septerna SEC filings (Ticker: SEPN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Septerna, Inc. (Nasdaq: SEPN) SEC filings, offering detailed regulatory disclosures about the company’s operations as a clinical-stage biotechnology company focused on G protein-coupled receptor (GPCR) drug discovery. As an issuer with common stock registered under Section 12(b) of the Exchange Act and listed on The Nasdaq Stock Market LLC or The Nasdaq Global Market, Septerna files current and periodic reports that describe its business, governance and financial condition.
Septerna’s Form 8-K filings frequently cover material events such as quarterly financial results and business highlights, including revenue, research and development expenses, general and administrative expenses, net income or loss, cash and marketable securities, working capital, total assets, total liabilities and stockholders’ equity. Other 8-Ks disclose collaboration agreements, such as the global collaboration and license agreement with Novo Nordisk A/S, leadership and board appointments, executive role changes, investor presentations and annual meeting voting results.
Through its SEC filings, Septerna also reports on matters like director elections, committee assignments, non-employee director compensation, and submission of matters to a vote of stockholders. These documents provide insight into the company’s corporate governance framework, including the composition of its board and committees and the outcomes of shareholder votes.
On Stock Titan, Septerna’s filings are updated in near real time as they are made available on EDGAR. AI-powered summaries help explain the key points of lengthy filings, so readers can quickly understand the implications of new 8-Ks and other reports without reviewing every page. Users can review historical filings to track trends in Septerna’s financials, follow the evolution of its collaborations and governance, and monitor ongoing disclosure about its GPCR-focused pipeline and clinical-stage programs.
Septerna, Inc. (SEPN) reported that Chief Medical Officer Rajiv Patni received a grant of stock options for 275,000 shares of common stock on September 8, 2026, at an exercise price of $37.37 per share, expiring on September 7, 2036. According to the vesting terms, 25% of the underlying shares vest on August 24, 2027 and the remaining 75% vest in thirty-six substantially equal monthly installments thereafter, subject to his continuous service, resulting in reported holdings of 275,000 options after this grant.
Septerna, Inc. (SEPN) filed an initial statement of beneficial ownership on behalf of Rajiv Patni, who serves as Chief Medical Officer. The filing reports no equity transactions or holdings for him at this time and includes an Exhibit 24 Power of Attorney authorizing the filing.
Septerna, Inc. insider Daniel D. Long, who serves as SVP, Drug Discovery, reported an option exercise and same‑day sale of common stock. On September 1, 2026, he exercised options to acquire 3,333 shares of common stock at an exercise price of $2.76 per share and sold 3,333 shares of common stock at a weighted average price of $37.8271 per share in multiple trades between $37.34 and $38.21.
The sale was effected pursuant to a Rule 10b5-1 sales plan adopted on March 20, 2026, indicating the transactions were pre‑planned. Following the option exercise, Long held 9,085 options on Septerna common stock with a $2.76 exercise price, expiring on March 19, 2034, which vest in substantially equal monthly installments from March 1, 2024, subject to his continued service.
Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company focused on G protein-coupled receptor (GPCR) drug discovery, announced the appointment of Rajiv Patni, M.D. as Chief Medical Officer, effective August 24, 2026. The appointment was communicated via an August 25, 2026 press release furnished as an exhibit.
Dr. Patni is a physician-scientist and biopharmaceutical executive with more than 25 years of experience leading research, development, regulatory and medical affairs organizations. He previously held senior roles including Chief Executive Officer of Judo Bio and Chief Research and Development Officer at Reata Pharmaceuticals, as well as Chief Medical Officer positions at several other biopharma companies.
Septerna highlights Dr. Patni’s track record contributing to programs that led to 10 regulatory agency approvals or label expansions across the United States, Europe and additional markets. The company describes itself as advancing a pipeline of novel oral small molecule drug candidates using its proprietary Native Complex Platform® in endocrinology, immunology, inflammation, metabolic diseases and other therapeutic areas.
Third Rock Ventures V, L.P. reported acquisition or exercise transactions in a Form 4 filing for SEPN. The filing lists transactions totaling 147,200 shares at a weighted average price of $50.27 per share from August 12, 2026 to August 12, 2026.
RA Capital Management and related entities report beneficial ownership of Septerna, Inc. common stock. The reporting group, including RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P., reports beneficial ownership of 5,525,324 shares of Septerna common stock, representing 11.8% of the class based on 46,676,947 shares outstanding as of August 5, 2026. Holdings include 4,777,415 shares held by RA Capital Healthcare Fund, 725,443 shares held by RA Capital Nexus Fund III, L.P., and 22,466 shares underlying vested stock options held by Dr. Simson for the benefit of RA Capital. On August 12, 2026, the Fund and Nexus Fund III each executed a block sale of 746,500 shares at $42.50 per share. Certain stock options vested in June and July 2026 with exercise prices of $10.24 and $6.81 per share. The funds have delegated sole voting and dispositive power to RA Capital and disclaim beneficial ownership for most purposes under Section 13(d).
RA Capital–affiliated entities reported open-market sales of Septerna, Inc. common stock. On 2026-08-12, RA Capital Healthcare Fund LP and RA Capital Nexus Fund III, L.P. each sold 746,500 shares of Septerna common stock at $42.50 per share, for total reported sales of 1,493,000 shares. The positions are reported as indirectly owned, with RA Capital Management, L.P., its general partner, and principals Peter Kolchinsky and Rajeev Shah disclaiming beneficial ownership beyond their respective pecuniary interests.
Driehaus Capital Management LLC reports beneficial ownership of common stock of Septerna, Inc. and amends its disclosure to reflect a change in ownership percentage. Driehaus reports beneficially owning 4,433,058 shares of Septerna common stock, representing 9.83% of the class.
Driehaus has shared voting power and shared dispositive power over all 4,433,058 shares, with no sole voting or dispositive power. The shares are held in numerous client accounts managed by Driehaus on a fully discretionary basis. Driehaus states that, to its knowledge, none of these underlying clients has the right to receive dividends or sale proceeds relating to more than 5% of the class.
Septerna, Inc. President and COO Elizabeth Bhatt exercised stock options for a total of 25,000 shares of Common Stock on August 11, 2026, including 18,681 shares at an exercise price of $6.81 and 6,319 shares at $2.76. On the same date, she sold 25,000 Common Stock shares at $44.00 per share. The sale was effected pursuant to a Rule 10b5-1 sales plan adopted on October 20, 2025, and certain options vest in monthly installments subject to her continued service.